JAGSONPAL PHARMACEUTICALS (JAGSNPHARM)

NSE: ₹203.45
BSE: ₹202.45
Stock Performance
Corporate Announcements
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Allotment of 2,96,320 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022.

2026-06-04 16:43:49
Announcement under Regulation 30 (LODR)-Closure of Buy Back

Extinguishment of 16,00,000 Equity Shares of Jagsonpal Pharmaceuticals Limited.

2026-06-02 15:48:01
Compliances-Reg.24(A)-Annual Secretarial Compliance

Please find enclosed Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026

2026-05-28 15:10:21
Announcement under Regulation 30 (LODR)-Newspaper Publication

Submission of copy of Post Buy Back Public Advertisement related to Buy back of shares of Company.

2026-05-25 14:53:40
2026-05-18 17:52:02
Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication regarding dispatch of Letter of Offer of Buy Back to the shareholders of the Company

2026-05-07 15:47:15
Submission Of Letter Of Offer For Buy-Back Upto 16,00,000 Equity Shares

Submission of Letter of Offer for Buy- Back upto 16,00,000 Equity Shares at price of INR-250/- per share amounting to INR-40,00,00,000/-

2026-05-06 20:13:20
Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Earning Call Transcript for meeting held on April 28, 2026

2026-05-04 16:52:42
Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Advertisement- Extract of Audited Financial Results for FY 26

2026-04-29 18:41:36

Quarterly Financials

Consolidated Standalone
Particulars Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 60.15 57.83 47.23 43.49 61.44 74.69 74.03 58.56 75.61 74.47 72.95 64.20
YOY Revenue Growth % -0.73% -4.46% -21.46% -21.58% 2.14% 29.16% 56.72% 34.66% 23.07% -0.3% -1.46% 9.64%
Other Income 2.00 2.27 2.52 2.49 1.44 1.65 2.32 2.77 2.83 3.03 2.98 3.17
Total Income 62.15 60.10 49.76 45.97 62.88 76.35 76.35 61.33 78.44 77.49 75.92 67.37
Total Expenses + 52.06 50.14 44.48 41.44 52.49 60.98 60.86 52.41 64.01 60.68 59.32 55.62
Cost of Materials Consumed 7.53 4.91 5.88 3.79 4.39 5.20 5.27 3.49 5.33 3.84 3.95 2.99
Employee Benefit Expense 13.70 11.70 11.64 11.45 14.74 16.68 18.08 16.57 19.44 18.18 17.58 15.55
Other Expenses 15.53 16.85 12.46 11.71 14.16 15.37 13.59 11.56 15.03 12.63 12.65 13.73
Operating Profit 8.09 7.69 2.76 2.05 8.95 13.72 13.17 6.15 11.61 13.78 13.63 8.59
OPM % 13.5% 13.3% 5.8% 4.7% 14.6% 18.4% 17.8% 10.5% 15.3% 18.5% 18.7% 13.4%
Profit Before Tax + 10.09 9.96 5.28 4.54 7.11 15.37 38.67 8.71 14.43 16.81 14.52 11.76
Tax Expense 2.61 2.49 1.32 0.99 1.78 3.91 6.68 2.13 3.64 4.24 3.57 2.99
Tax % 25.9% 25% 24.9% 21.8% 25% 25.4% 17.3% 24.4% 25.2% 25.2% 24.6% 25.5%
Profit After Tax 7.48 7.47 3.96 3.55 5.33 11.46 31.99 6.58 10.80 12.57 10.95 8.76
EPS (Basic) 2.85 2.84 1.48 1.31 1.94 4.29 4.74 0.98 1.60 1.88 1.67 1.25

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
Revenue from Operations 287.23 268.72 208.70 236.71 226.10 187.95 158.57
YOY Revenue Growth % 6.89% 28.76% -11.83% 4.7% 20.3% 18.53% -
Other Income 12.00 8.19 9.28 5.73 3.34 4.39 2.53
Total Income 299.22 276.91 217.98 242.45 229.43 192.34 161.09
Total Expenses + 239.62 226.73 188.11 204.18 202.11 170.47 130.63
Cost of Materials Consumed 16.11 18.34 22.10 31.21 40.42 38.63 36.78
Employee Benefit Expense 70.74 70.93 48.49 56.41 57.68 53.98 50.37
Other Expenses 54.04 50.27 57.17 53.04 46.84 34.11 43.47
Operating Profit 47.60 41.98 20.59 32.53 23.98 17.48 27.93
OPM % 16.6% 15.6% 9.9% 13.7% 10.6% 9.3% 17.6%
Profit Before Exceptional 59.60 50.17 29.87 38.27 27.32 21.87 9.41
Exceptional Items -2.08 19.69 0.00 -3.46 0.00 0.00 0.00
Profit Before Tax + 57.52 69.86 29.87 34.81 27.32 21.87 9.41
Tax Expense 14.44 14.50 7.41 8.09 7.73 4.81 1.54
Tax % 25.1% 20.8% 24.8% 23.2% 28.3% 22% 16.4%
Profit After Tax 43.08 55.36 22.46 26.72 19.59 17.06 7.87
EPS (Basic) 6.40 8.26 8.49 10.20 7.48 6.51 3.00

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
ASSETS
Non-Current Assets + 173.59 117.07 17.82 30.39 57.68 43.73 0.00
Property, Plant & Equipment 0.57 0.61 0.91 18.35 22.37 23.35 0.00
Capital Work in Progress 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Non-Current Investments 0.00 0.00 0.00 1.12 20.58 12.06 0.00
Goodwill 9.69 9.69 0.00 0.00 0.03 0.03 0.00
Other Intangible Assets 75.04 84.15 8.39 5.93 2.35 0.00 0.00
Current Assets + 143.09 161.19 199.25 164.56 110.78 120.48 0.00
Inventories 14.64 15.20 15.00 20.68 29.74 29.72 0.00
Trade Receivables 17.19 13.18 10.95 20.87 15.58 12.66 0.00
Cash and Cash Equivalents 10.04 11.22 12.76 11.05 26.03 58.94 0.00
Current Investments 0.00 0.00 0.00 0.00 22.14 0.00 0.00
LIABILITIES & EQUITY
Total Equity 276.17 239.95 187.40 158.89 130.86 121.93 0.00
Equity Share Capital 13.39 13.28 13.22 13.10 13.10 13.10 0.00
Other Equity 262.78 226.67 174.18 145.79 117.76 108.83 0.00
Non-Current Liabilities 12.21 12.41 10.55 8.48 3.44 1.88 0.00
Current Liabilities 28.30 25.90 19.13 27.57 34.16 40.40 0.00
Total Liabilities 40.51 38.31 29.68 36.06 37.60 42.27 0.00

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
Cash from Operating Activities 46.81 55.30 35.17 40.15 5.60 28.22 0.00
Cash from Investing Activities -35.65 -45.15 -24.55 -51.62 -26.21 -2.26 0.00
Cash from Financing Activities -12.15 -11.70 -8.91 0.00 -12.30 -6.83 0.00
Net Increase/Decrease in Cash -0.99 -1.55 1.71 -11.47 -32.91 19.13 0.00